India is being given a constant tariff threats to India from the US and now once again Donald Trump has made a new threat, targeting the pharma sector. Yes, we are talking about the pharma sector, on which the US President has threatened to impose tariffs up to 250 percent, not 50-100 percent (US TARIFF on PHARMA). Its direct impact was also seen on Indian companies associated with this sector and their shares were seen disintegrating during the business. Shares from Ajantfharma, Biocon to Zides fell.
What has Trump threatened?
First of all, let us tell you what Trump has said in his new threat and why can it become a big problem for India? So let us tell you that the US President talked about putting high tariffs on US drug imports in the White House. However, it will be implemented in a phased manner. Trump said that first a small tariff would be installed on the pharma sector and in the next 18 months it will be increased directly to 150% and then reaching 250%. The President has described it as a step taken to promote US domestic production.
Company’s name falls share 1.80% 32,740 rupees DR Reddy’s Lab 1.50% 1197.50 Glenmark Pharma 1.50% 2005.10 rupees
The US is a major importer of medicines and other pharma products and it can be gauged from the fact that in 2024 last year US imports in the region reached $ 234 billion. America’s largest suppliers included Ireland, Switzerland, Germany, Italy, China, Britain, Japan and India. Last year, imports from India were 6 percent of total American imports, which cost more than $ 13 billion. Let us tell you that India exports the largest part of its pharma products to the US. Especially there is a strong demand for India’s generic medicines. In such a situation, Trump’s tariff can become a problem for companies connected to this region.
As soon as the announcement was made, the effect started appearing
Trump’s immediate impact of the threat of putting tariffs on the pharma sector is also being seen. The stock market saw a huge decline in shares of all Indian pharma companies amid the recession. The Sun Pharma Company’s stock included about 2 per cent of BSE’s largecap companies, nearly 2 per cent to around Rs 1600. At the same time, Glaxo Smithkline Pharma’s stock included in midcap was trading more than 3 per cent decline. Talking about other companies in the pharma sector …
